Sionna Therapeutics' stock dropped 92% after its Phase 2a trial for cystic fibrosis drug SION-719 failed to meet key endpoints, notably reducing sweat chloride levels. This disappointing result has led shareholder rights firm Robbins LLP to investigate potential securities law violations and breaches of fiduciary duty by company officers. Despite having substantial financial resources, Sionna plans to conserve capital while deciding the future of its clinical pipeline. Shareholders who suffered losses are encouraged to contact Robbins LLP for legal assistance.
XRP's on-chain trading volume has increasingly concentrated during a three-hour window overlapping London and New York business hours, capturing 23.5% of weekday volume in July 2026, up from 14.3% a year earlier. This shift suggests growing instituti...
Suja Life, a producer of organic juices, saw its stock drop more than 70% below its IPO price after reporting a 21% sales decline and a 7.5% drop in gross profit margins in Q2 2026. The company cut its full-year revenue and growth forecasts, citing s...
Teradyne (TER) has been upgraded from Hold to Buy due to robust multi-year growth driven by increasing demand for chip testing amid expanding data centers and chip complexity. The company's premium price-to-earnings ratio of 48.74x is supported by st...
Ferrovial has been selected to deliver Tennessee's I-24 Southeast Choice Lanes, the state's largest private infrastructure investment at $9.2 billion. The 26-mile project will add choice lanes to ease congestion between Nashville and Murfreesboro, im...
SKYAI cryptocurrency fell 18% in the last 24 hours, extending a week-long bearish correction after a recent breakout. Despite the price drop, trading volume surged 65%, indicating increased market activity but unclear control between buyers and selle...
